Orforglipron

Overview

Orforglipron (LY3502970, also known as Foundayo) is a first-in-class oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike all other GLP-1 agonists which are peptide-based (requiring injection or complex oral formulation), orforglipron is a small molecule that can be taken as a simple daily tablet. Phase 2 clinical data demonstrated approximately 12% average weight loss at the highest dose — remarkable for an oral compound. It represents a paradigm shift in GLP-1 research: achieving incretin receptor activation through a non-peptide molecular scaffold.

Mechanism of Action

Orforglipron is a small molecule that acts as a full agonist at the GLP-1 receptor through a binding site that partially overlaps with but is distinct from the peptide ligand binding domain. It activates Gs-protein signalling and cAMP production, triggering the same downstream cascade as peptide GLP-1 agonists — including insulin potentiation, glucagon suppression, gastric emptying delay, and hypothalamic satiety signalling. Its non-peptide nature confers oral bioavailability without the need for absorption enhancers (unlike oral semaglutide) and provides a half-life suitable for once-daily dosing.

Research Applications

• Non-peptide GLP-1 receptor agonist pharmacology research
• Oral GLP-1 bioavailability and pharmacokinetics studies
• Small molecule vs peptide receptor activation comparison
• Metabolic parameter research with oral delivery
• GLP-1 receptor binding site topology and allosteric modulation